New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts. Especially urgent are discussions on ...

Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history of treatment ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place this week in Rwanda, a country of just over 14 million people that has become a continental leader in HIV ...

Six poster presentations at last month’s British HIV Association (BHIVA) Conference in Brighton found that only a minority of people with HIV are being offered and starting to take the ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

📢 With heavy hearts, we announce the proposed closure of our beloved charity, NAM aidsmap, this month. After 37 years of pioneering health journalism, community engagement, and empowerment through ...

Matthew Hodson has decided to stand down as Executive Director of aidsmap. This marks the end of a significant era for the organisation and the HIV community. Matthew has been a formidable leader, ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

A cohort of people with HIV who took NRTIs (a class of HIV drugs) as part of HIV treatment showed lower rates of Alzheimer’s disease than people without HIV. The team of American researchers behind ...

A symposium at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) earlier this month included presentations advocating changes in practice on what might be called opposite ends of ...

A longer-acting formulation of cabotegravir may offer an HIV pre-exposure prophylaxis (PrEP) and treatment option that could be administered once every four months, according to early study ...